Obesity Market Spotlight, 2020: Epidemiology, Marketed & Pipeline Drugs, Revenue Opportunities, Clinical Trial Landscape - ResearchAndMarkets.com
The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
- The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
- The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III.
- Clinical trial activity in the obesity space is dominated by completed trials.
- Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.